Conference Details

Event Categories

Browse C5 Companies

C5 Group
www.C5groupinc.com

Canadian Institute
www.canadianinstitute.com

American Conference Institute
www.americanconference.com
C5 (UK) : Maximising Pharma Patents : OVERVIEW

12th International Forum on

Maximising Pharma Patents

Tuesday, June 25 to Wednesday, June 26, 2013
Kensington Close Hotel, London

Strategies to maximise pharma patents will be significantly transformed. In February 2013 the European Commission will be publishing final draft rules on unitary patent and the unified patents court. Understanding the new legal regime and how these changes will affect pharma patent is essential for the pharma industry.

The 12th International Forum on Maximising Pharma Patents will bring together eminent in-house counsel from the world’s largest pharma and biotech companies and their expert advisors from a range of jurisdictions, including the US, Europe and Asia. A special keynote address will be given by leading judge on the unitary patent and the unified patents court.

The forum will include analysis of new procedural rules published by the European Commission on unitary patent and its impact on pharma patent management. Panel speakers will be leading judges, regulatory experts, and industry specialists speaking on how it will work in practice.

Judicial authorities will speak on SPC procedures, recent cases referred to the European Court of Justice on the scope of SPCs and the impact of the pending decisions for pharma patent extensions. Based on their first-hand experience, the distinguished panel will provide you with invaluable information and insights on pharma patent with a particular focus on:

  • Understanding the challenges, risks, and opportunities of the proposed unitary patent. How the proposed unitary patent compares with the current European patent. Where and how you will be able to sue for infringement or challenge validity in Europe, in terms of what judges, what languages, and what type of procedure will be involved?
  • Why will London be important for Pharma and biotech patents? What strategies should be considered during the transition to the new system?
  • Scope of SPCs for combination products and the cases referred to the ECJ.
  • Employing recent cases on SPCs in Europe and the US to file successful applications.
  • Examining potential anti-competitive practices and recent patent settlement agreements.
  • Guidance from the EU Commission on lifecycle extensions.

Be where your industry will be on 25th and 26th June 2013 and don’t miss out on this unique opportunity to hear from and network with prominent judicial authorities, regulatory experts and industry specialists.


For speaking opportunities please contact:
Tony Ram, conference producer
Tel: +44(0)20 7878 6980
Email: t.ram@c5-online.com

For sponsorship opportunities please contact :
Daniel Capel
Tel : +44(0)20 7878 6870
Email : d.capel@c5-online.com

For media partnership opportunities please contact:
Karina Kusova
Tel : +44(0)20 7878 6956
Email : k.kusova@c5-online.com